Odyssey Therapeutics, Inc. ODTX
20.99 USD +0.99 (+4.95%)
At closeNov 11, 2026, 4:00 PM EST
20.99 0.00 0.00%
After hours · Nov 11, 4:00 PM ET
19.22 Day range 21.21
15.10 52-week range 29.05
- YTD
- +27.83%
- 1 year
- +27.83%
News
benzinga.com Odyssey Therapeutics Publishes Paper Titled 'TNFR2 agonism increases tissue and effector Treg cells In Journal Of Immunology Odyssey Therapeutics, Inc. (Nasdaq: ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and
globenewswire.com Odyssey Therapeutics Announces Publication Highlighting Differentiated Therapeutic Potential of TNFR2 Agonism “Cutting Edge” article demonstrates that compared with IL-2, TNFR2 agonism promotes tissue-directed regulatory T-cell differentiation and lineage stability, as well as reduces autoimmune inflammation…
benzinga.com HC Wainwright & Co. Assumes Odyssey Therapeutics at Buy, Announces Price Target of $40 HC Wainwright & Co. analyst Joseph Pantginis assumes Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $40.
benzinga.com Odyssey Therapeutics Q3 EPS $(1.10) Misses $(1.08) Estimate Odyssey Therapeutics (NASDAQ:ODTX) reported quarterly losses of $(1.10) per share which missed the analyst consensus estimate of $(1.08) by 1.85 percent.
benzinga.com UBS Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $27 UBS analyst Alice Nettleton initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $27.
benzinga.com Odyssey Therapeutics To Present Design Of Randomized, Double-Blind Phase 2a Trial Evaluating OD-001 In Combination With Vedolizumab In Patients With UC At ACG 2026 Annual Scientific Meeting Odyssey Therapeutics, Inc. (NASDAQ:ODTX) ("Odyssey" or the "Company"), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and